MX361716B - Formulaciones peptidicas de liberacion controlada. - Google Patents

Formulaciones peptidicas de liberacion controlada.

Info

Publication number
MX361716B
MX361716B MX2013013401A MX2013013401A MX361716B MX 361716 B MX361716 B MX 361716B MX 2013013401 A MX2013013401 A MX 2013013401A MX 2013013401 A MX2013013401 A MX 2013013401A MX 361716 B MX361716 B MX 361716B
Authority
MX
Mexico
Prior art keywords
controlled release
compositions
forming
peptide formulations
release peptide
Prior art date
Application number
MX2013013401A
Other languages
English (en)
Other versions
MX2013013401A (es
Inventor
Tiberg Fredrik
Nistor Catalin
Johnsson Markus
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46456496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX361716(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of MX2013013401A publication Critical patent/MX2013013401A/es
Publication of MX361716B publication Critical patent/MX361716B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)

Abstract

La presente invención se refiere a composiciones que forman una mezcla de baja viscosidad de: a) 20-80 % en peso de al menos un diacil glicerol y/o un tocoferol; b) 20-80 % en peso de al menos una fosfatidilcolina (PC) ; c) 5-20 % en peso de al menos un solvente monoalcohólico orgánico, biocompatible; d) hasta 20 % en peso de solvente polar e) al menos un agente activo peptídico; f) opcionalmente al menos un antioxidante;, en donde la relación de componentes a:b está en el intervalo 40:60 a 54:46; en donde la preformulación forma, o es capaz de formar, al menos una estructura de fase cristalina líquida después del contacto con fluido acuoso en exceso. La invención además se refiere a métodos de tratamiento que comprenden la administración de tales composiciones, y a dispositivos de administración prellenados y kits que contienen las formulaciones.
MX2013013401A 2011-05-25 2012-05-25 Formulaciones peptidicas de liberacion controlada. MX361716B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161489886P 2011-05-25 2011-05-25
PCT/EP2012/059917 WO2012160213A1 (en) 2011-05-25 2012-05-25 Controlled release peptide formulations

Publications (2)

Publication Number Publication Date
MX2013013401A MX2013013401A (es) 2013-12-12
MX361716B true MX361716B (es) 2018-12-14

Family

ID=46456496

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013401A MX361716B (es) 2011-05-25 2012-05-25 Formulaciones peptidicas de liberacion controlada.

Country Status (35)

Country Link
US (2) US11433120B2 (es)
EP (2) EP4427814A2 (es)
JP (2) JP6265888B2 (es)
KR (1) KR102066755B1 (es)
CN (2) CN108283619B (es)
AR (1) AR086577A1 (es)
AU (2) AU2012260821B2 (es)
BR (1) BR112013030104A8 (es)
CA (1) CA2836847C (es)
CL (1) CL2013003365A1 (es)
CO (1) CO6900117A2 (es)
CR (1) CR20130653A (es)
CU (1) CU20130158A7 (es)
DK (1) DK2714004T3 (es)
DO (1) DOP2013000275A (es)
EA (1) EA036213B1 (es)
EC (1) ECSP13013107A (es)
FI (1) FI2714004T3 (es)
GT (1) GT201300292A (es)
HR (1) HRP20240781T1 (es)
IL (1) IL229376B (es)
LT (1) LT2714004T (es)
MX (1) MX361716B (es)
MY (1) MY177820A (es)
NI (1) NI201300127A (es)
PE (1) PE20141484A1 (es)
PH (1) PH12013502550A1 (es)
PL (1) PL2714004T3 (es)
PT (1) PT2714004T (es)
RS (1) RS65702B1 (es)
SG (1) SG194865A1 (es)
SI (1) SI2714004T1 (es)
TW (1) TWI624271B (es)
WO (1) WO2012160213A1 (es)
ZA (1) ZA201309653B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ551990A (en) * 2004-06-04 2011-01-28 Camurus Ab Liquid depot formulations
US9107904B2 (en) * 2012-04-05 2015-08-18 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
MA37672A1 (fr) * 2012-05-25 2016-07-29 Camurus Ab Formulation d'agoniste des récepteurs à la somatostatine
AU2013294915C1 (en) 2012-07-26 2019-11-21 Camurus Ab Opioid formulations
US10300145B2 (en) 2016-07-15 2019-05-28 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
ES2933175T3 (es) 2016-09-15 2023-02-02 Camurus Ab Formulaciones de análogos de prostaciclina
TWI805558B (zh) 2016-09-27 2023-06-21 瑞典商凱慕路斯公司 混合物與配方
EP3551210A1 (en) 2016-12-07 2019-10-16 RA Pharmaceuticals, Inc. Modulators of complement activity
WO2019099735A1 (en) * 2017-11-15 2019-05-23 Rhythm Pharmaceuticals, Inc. Sustained release peptide formulations
CN109091451B (zh) * 2018-09-10 2021-08-13 武汉百纳礼康生物制药有限公司 亲水性药物的油相液晶凝胶前体制剂及其制备方法
CN113993535A (zh) * 2019-05-29 2022-01-28 卡姆拉斯公司 脂质控释组合物
CN113368041B (zh) * 2020-07-17 2023-01-03 丽珠医药集团股份有限公司 药物组合物、缓释制剂及其制备方法
CN117241822A (zh) * 2021-05-04 2023-12-15 卡姆拉斯公司 用于治疗神经内分泌肿瘤的组合物和方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046642A1 (en) * 2003-11-07 2005-05-26 Camurus Ab Compositions of lipids and cationic peptides
WO2006075124A1 (en) * 2005-01-14 2006-07-20 Camurus Ab Somatostatin analogue formulations
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
NZ551990A (en) * 2004-06-04 2011-01-28 Camurus Ab Liquid depot formulations
GB0417388D0 (en) * 2004-08-04 2004-09-08 Camurus Ab Composition
ES2383530T3 (es) 2004-08-04 2012-06-22 Camurus Ab Composiciones que forman dispersiones no laminares
SI1845942T1 (sl) * 2005-01-14 2014-06-30 Camurus Ab Gnrh analogne formulacije
KR101245022B1 (ko) * 2005-01-21 2013-03-19 카무러스 에이비 약제학적 지질 조성물
CN101193652B (zh) * 2005-04-08 2011-11-02 安米林药品公司 包含肠降血糖素肽和非质子极性溶剂的药物制剂
CN101217940B (zh) * 2005-06-06 2013-03-27 卡穆鲁斯公司 Glp-1类似物制剂
GB0711656D0 (en) * 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) * 2007-08-22 2007-10-03 Camurus Ab Formulations
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
US8931272B2 (en) * 2010-10-29 2015-01-13 Ford Global Technologies, Llc Method and system for limiting output of a boosted engine
US9585959B2 (en) * 2011-12-05 2017-03-07 Camurus Ab Robust controlled-release formulations
MA37672A1 (fr) * 2012-05-25 2016-07-29 Camurus Ab Formulation d'agoniste des récepteurs à la somatostatine
US20230285502A1 (en) * 2016-09-07 2023-09-14 Camurus Ab Mixtures and formulations
TWI805558B (zh) * 2016-09-27 2023-06-21 瑞典商凱慕路斯公司 混合物與配方

Also Published As

Publication number Publication date
EP2714004B1 (en) 2024-05-15
MX2013013401A (es) 2013-12-12
AU2012260821B2 (en) 2016-01-07
BR112013030104A8 (pt) 2021-09-08
CN103702662A (zh) 2014-04-02
DOP2013000275A (es) 2014-05-15
US20140162944A1 (en) 2014-06-12
DK2714004T3 (da) 2024-06-10
SI2714004T1 (sl) 2024-07-31
CO6900117A2 (es) 2014-03-20
CU20130158A7 (es) 2014-04-24
NI201300127A (es) 2014-02-25
MY177820A (en) 2020-09-23
AR086577A1 (es) 2014-01-08
PH12013502550B1 (en) 2015-08-10
SG194865A1 (en) 2013-12-30
JP2018076327A (ja) 2018-05-17
JP2014520090A (ja) 2014-08-21
FI2714004T3 (fi) 2024-07-15
PT2714004T (pt) 2024-07-12
CR20130653A (es) 2014-03-05
TW201249463A (en) 2012-12-16
NZ617828A (en) 2016-11-25
RS65702B1 (sr) 2024-07-31
PH12013502550A1 (en) 2015-08-10
IL229376B (en) 2019-11-28
US11433120B2 (en) 2022-09-06
PE20141484A1 (es) 2014-10-31
TWI624271B (zh) 2018-05-21
GT201300292A (es) 2014-08-05
PL2714004T3 (pl) 2024-08-19
EA036213B1 (ru) 2020-10-14
EP4427814A2 (en) 2024-09-11
HRP20240781T1 (hr) 2024-09-13
CA2836847A1 (en) 2012-11-29
AU2016202156A1 (en) 2016-04-28
KR20140045438A (ko) 2014-04-16
CN108283619B (zh) 2021-09-14
US20210308226A1 (en) 2021-10-07
CA2836847C (en) 2021-06-29
CN108283619A (zh) 2018-07-17
EA201391675A1 (ru) 2014-08-29
BR112013030104A2 (pt) 2016-09-20
ECSP13013107A (es) 2015-03-31
JP6265888B2 (ja) 2018-01-24
WO2012160213A1 (en) 2012-11-29
KR102066755B1 (ko) 2020-01-15
JP6415673B2 (ja) 2018-10-31
IL229376A0 (en) 2014-01-30
EP2714004A1 (en) 2014-04-09
ZA201309653B (en) 2016-05-25
LT2714004T (lt) 2024-08-12
CL2013003365A1 (es) 2014-07-25
AU2016202156B2 (en) 2018-03-22
CN103702662B (zh) 2018-07-20

Similar Documents

Publication Publication Date Title
MX361716B (es) Formulaciones peptidicas de liberacion controlada.
MX352024B (es) Formulaciones potentes de liberacion controlada.
AR083016A1 (es) Formulaciones liquidas para la agricultura con una mejor estabilidad
CL2015001945A1 (es) (divisional de la solicitud n° 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
MX2018003333A (es) Formulaciones de liberacion controlada.
BR112012006686B8 (pt) compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa
ATE501710T1 (de) Somatostatin-analog-formulierungen
EA201791166A1 (ru) Препараты с контролируемым высвобождением
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
MX2019008650A (es) Composicion de ingredientes activos liposolubles estables, microcapsula y su proceso de preparacion y uso.
TN2014000483A1 (en) Somatostatin receptor agonist formulations
BR112012015433B8 (pt) composição farmacêutica substancialmente anidra para aplicação cutânea
MX2019003520A (es) Mezclas y formulacions que comprenden una sal de alquil amonio de acido etilendiaminotetraacetico (edta).
IL251413B1 (en) Composition of injectable buprenorphine
MX2019002999A (es) Formulaciones de analogo de prostaciclina.
BR112021023549A2 (pt) Composições terapêuticas estáveis em solventes polares apróticos e seus métodos de fabricação
MX362592B (es) Supresion de olor de los compuestos analgesicos organicos volatiles y metodo de uso.
EA201201480A1 (ru) Адгезионные ретардированные составы для местного применения куркумина
TH1301006692A (th) สูตรผสมเปปไทด์ที่ปลดปล่อยยาในอัตราคงที่
IN2013MU03800A (es)

Legal Events

Date Code Title Description
FG Grant or registration